Bill revision could mean money for NJ drug company
Thursday, June 30, 2011 - 04:30
in Mathematics & Economics
(AP) -- A billion-dollar "technical revision" added to a patent bill passed by the House last week could provide huge financial benefits to one pharmaceutical company and a law firm.